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Abstract Combined use of MammaPrint and a molecular
subtyping profile (BluePrint) identifies disease subgroups
with marked differences in long-term outcome and
response to neo-adjuvant therapy. The aim of this study
was to evaluate the prognostic value of molecular subtyp-
ing using MammaPrint and BluePrint in women with early-
stage breast cancer (BC) treated at US institutions fol-
lowing National Comprehensive Cancer Network standard
guidelines. Tumor samples were collected from stage 1-2B
consecutively diagnosed BC patients (n = 373) who
underwent lumpectomy or mastectomy with an axillary
staging procedure between 1992 and 2010 at two institutes
(NorthShore University HealthSystem and Fox Chase
Cancer Center) in the United States of America, with a
median follow-up time of 9.5 years. MammaPrint low-risk
patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4),
while MammaPrint high-risk patients had a 10-year DMFS
of 87 % (95 %CI 81.9–92.1) with a hazard ratio of 3.62
(95 %CI 1.38–9.50) (p = 0.005). Uni- and multivariate
analyses included age, tumor size, grade, ER, and Her2; in
multivariate analysis, MammaPrint reached near-signifi-
cance (HR 3.01; p 0.08). When comparing BluePrint
molecular subtyping with clinical stratification, the prog-
nosis (10-year DMFS) was significantly different in
10-year DMFS between the different molecular subtypes
(p\ 0.001). This retrospective study with 10-year follow-
up data provides valuable insight into prognosis of patients
with primary BC comparing clinical with molecular sub-
typing. The BluePrint molecular stratification assay iden-
tifies patients with significantly different outcomes
compared with standard clinical molecular stratification.
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Introduction
Improved understanding of the molecular phenotypes of
breast cancer (BC) has already shown prognostic and
predictive value and, when prospectively applied, could
have dramatic implications in establishing a more person-
alized approach to the management of early-stage breast
cancer. The St. Gallen Expert Consensus Guidelines for the
recommendations of treatment in early-stage BC have
recognized the importance of disease subtype classification
and have included the surrogate pathology-based subtype
classification definitions in lieu of medically accepted
molecular classification techniques [1].
The rational-based method (supervised training) for
development of the 80-gene molecular subtyping profile
(BluePrint) is inherently different from the groundbreaking
research used originally to unveil the existence of molec-
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The 80-gene molecular subtyping profile (BluePrint) has
been developed to provide a molecular classification
technique based on gene expression of three functional and
targetable pathways that distinguish Luminal-type versus
HER-2-type, versus Basal-type. A rational-based method
was used to ensure a robust and reproducible profile with
concordant immunohistochemistry (IHC)/fluorescent
in situ hybridization (FISH)-assessed and mRNA-assessed
training samples for the estrogen receptor (ER), proges-
terone receptor (PR), and HER2. BluePrint determines the
mRNA expression levels of 80 genes that best discriminate
between luminal-type, HER2-type, and basal-type tumors
and was validated using four independent validation
cohorts consisting of 784 patients [3]. The luminal subtype
can be further divided into luminal-type A (low risk) and
luminal-type B (high risk) using MammaPrint.
The clinical utility of BluePrint molecular classification
was demonstrated in a previously published retrospective
analysis of four pooled neo-adjuvant studies. In that cohort,
90 of 437 (21 %) patients were classified as luminal-type
A. These patients, who could not be identified by standard
IHC/FISH for ER, PR, HER2 biomarkers, demonstrated a
distant metastasis-free survival rate of 93 % at 5 years and
showed little, if any, benefit from chemotherapy (the pCR
rate was only 6 % in this group) [4].
The aim of the current retrospective study was to eval-
uate the prognostic implication of accurate molecular
subtyping using MammaPrint and BluePrint in women with
early-stage BC treated in the adjuvant setting with 10-year
follow-up at two US Institutions following National
Comprehensive Cancer Network (NCCN) standard
guidelines.
Patients and methods
Patients and tumor samples
Frozen (n = 205) and formalin-fixed paraffin-embedded
(FFPE) tissue (n = 168) tumor samples were collected
from stage 1-2B consecutively diagnosed BC patients who
underwent lumpectomy or mastectomy with an axillary
staging procedure between 1992 and 2010 at two institutes
[NorthShore University HealthSystem (n = 275) and Fox
Chase Cancer Center (n = 98)] in the United States of
America. The median follow-up time of this patient cohort
was 9.5 years. Clinical and histopathological data from all
patients were collected.
Local pathological assessment of ER, PR, and Her2
Methods and cutoffs for local assessment of ER, PR, and
HER2 varied during the years encompassed by this study.
At NorthShore, a 20 % staining threshold was used to
determine ER and PR status until 2002, at which time a
1 % threshold was instituted. Different antibody clones
were also utilized over this time period, including Dako
6F11, 1D5, and SP1 for ER and 1294 for PR. For HER2
testing, older cases were analyzed using the Dako Her-
ceptest. Subsequently, IHC using the Zymed Tab 250 or
Ventana 4B5 antibody followed by FISH testing for
equivocal cases was performed. IHC was scored as 0–3?
using standard criteria. A single probe FISH test (Ventana)
was scored as either negative (\4 signals/cell), equivocal
(4–6 signals/cell), or positive ([6 signals/cell). The most
recent cases were analyzed using the INFORM (Ventana)
chromogenic in situ dual probe system and scored based on
the HER2:CEP17 ratio as negative (ratio\ 1.8), equivocal
(ratio 1.8–2.2), or positive (ratio[ 2.2).
Molecular subtyping
Microarray analysis for obtaining the BluePrint and
MammaPrint signatures was done by staff at Agendia
Laboratories, Amsterdam, who were blinded to clinical and
pathological data. Expression data were quantified using
Feature Extraction software [5]. Four distinct molecular
subgroups—luminal A-type, luminal B-type, basal-type,
and HER2-type—were identified and used for further
analysis. In this study, we defined luminal A-type tumors
as luminal-type by BluePrint with a low-risk score by
MammaPrint and luminal B-type tumors as BluePrint
luminal-type with a MammaPrint high-risk score.
Central re-assessment of IHC/FISH
Patients who had a discordant subtype classification
[BluePrint vs. clinical (IHC/FISH)] were centrally re-
assessed for ER, PR, and Her2.
In the central laboratory, ER and PR statuses were
assessed on FFPE tissue by IHC using the ER/PR
PharmDX kit (Dako, Glostrup, Denmark). Tumors were
classified as ER- or PR-positive when C1 % invasive
tumor cells showed definite nuclear staining, irrespective of
staining intensity [6]. HER2 expression was evaluated with
the HercepTest kit (Dako) and scored as 0, 1?, 2?, or 3?,
according to the FDA scoring system. Tumors scored as
2? were re-tested with SISH using the PathVysion HER2
DNA probe kit (Vysis-Abbott, Chicago, USA). Cases were
considered HER2-positive if scored 3? by IHC and/or
amplified by SISH (ratio[ 2).
Statistical analyses
The primary end point was distant metastases-free survival
(DMFS), which was defined as the probability that patients
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remain free of distant metastases as the first event; data on
all other patients were censored on the date of the last
follow-up visit or date of death. Data were analyzed from
the date of surgery to the time of the first event or the date
on which data were censored, according to the Kaplan–
Meier method, and the curves were compared with use of
the log-rank test. In order to determine the independence of
MammaPrint to clinic-pathological variables in predicting
an individual’s risk of developing distant metastases, we
analyzed the results using univariate and multivariate
analysis. Variables included MammaPrint; age; tumor size;
grade; ER status; and HER2 status. All calculations were
performed with SPSS statistical package version 22.0
(SPSS, Chicago, IL).
Results
The clinical characteristics of the 373 patients (median age
56 range 28–97 years) are shown in Table 1. Two-hundred
and seventy-five (74 %) patients had ER-positive disease,
62 (17 %) had Her2-positive, and 73 (20 %) triple-negative
disease. Two-hundred and sixty-eight (72 %) patients had
lymph node negative disease. A total of 217 (58 %)
patients received adjuvant chemotherapy (CT) and 244
(65 %) adjuvant endocrine therapy (ET). Since most
patients were diagnosed prior to 2005, only 11 out of 62
(18 %) patients with Her2-positive disease received adju-
vant trastuzumab (H). For 64 %, the chemotherapy regi-
men was known and consisted of standard anthracycline-
regimens. Most patients (84 %) received AC (doxoru-
bicin/cyclophosphamide)/FAC (cyclophosphamide/dox-
orubicin/fluorouracil) or FEC (cyclophosphamide/
epirubicin/fluorouracil), followed by TAC (docetaxel/
doxorubicin/cyclophosphamide) (12 %), and CMF
(cyclophosphamide/methotrexate/fluorouracil) (6 %).
MammaPrint classified 152 (41 %) tumors as low-risk
and 221 (59 %) as high-risk. The combined analysis of
BluePrint and MammaPrint molecular subtyping classified
150 (40 %) tumors as luminal A-type, 102 (27 %) patients
as luminal B-type, 37 (10 %) tumors as HER2-type, and 84
(23 %) tumors as basal-type. Surrogate pathology-based
molecular classification using IHC/FISH for ER, PR, and
Her2 identified 238 (64 %) tumors as HR-positive (‘‘lu-
minal’’), 62 (17 %) tumors as Her2-positive, and 73 (20 %)
tumors as triple-negative (‘‘basal’’).
Interestingly, 17 out of 238 (7 %) IHC/FISH HR-posi-
tive (‘‘surrogate luminal’’) tumors were identified not
classified as luminal-type by BluePrint and were re-clas-
sified, two were HER2-type and 15 basal-type. Thirty-three
out of 62 (53 %) identified by IHC/FISH as Her2? tumors
Table 1 Clinical characteristics
Characteristic Number of patients
(percentage)
Age 56 years (range 28–97)
Ethnicity
Caucasian 320 (86 %)
African American 23 (6 %)
Asian 9 (2 %)
Other 21 (6 %)
Stage
Stage 1 167 (45 %)
Stage 2A 135 (36 %)
Stage 2B 71 (19 %)
Lymph nodes
0 268 (72 %)
1–3 84 (23 %)
[3 17 (5 %)
Unknown 4 (1 %)
Grade
Grade 1 67 (18 %)
Grade 2 121 (32 %)
Grade 3 180 (48 %)
Grade unknown 5 (1 %)
Surgery
Mastectomy 106 (28 %)
Lumpectomy 265 (71 %)
Surgery unknown 2 (1 %)
Local IHC/FISH
ER-positive 275(74 %)
PR-positive 208 (56 %)
Her2-positive 62 (17 %)
Treatment
No treatment 35 (9 %)
ET 121 (32 %)
CT 89 (24 %)
ET ? CT 117 (31 %)
CT ? H ± ET 11 (3 %)
CT regimen
AC/FAC/FEC 115 (53 %)
TAC 16 (7 %)
CMF 8(4 %)
Unknown* 78 (36 %)
* No details about the CT regimen were known for Fox Chase Cancer
Center patients
IHC immuno histochemistry, FISH fluorescent in situ hybridisation,
ER estrogen receptor, PR progesterone receptor, HER2 human epi-
dermal growth factor receptor 2, ET endocrine treatment, CT
chemotherapy treatment, H trastuzumab, A doxorubicin, C cy-
clophosphamide, F fluorouracil, E epirubicin, T docetaxel or pacli-
taxel, M methotrexate
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were re-classified by BluePrint as luminal-type (24) and
basal-type (9). Moreover, 13 out of 73 (18 %) triple-neg-
ative (‘‘surrogate basal’’) tumors were identified by Blue-
Print as luminal-type (7) and HER2-type (6) (Fig. 1).
MammaPrint 10-year DMFS validation
The Kaplan–Meier survival curves (Fig. 2a) show that
MammaPrint low-risk patients had a 10-year DMFS of 96 %
(95 %CI 92.8–99.4), while MammaPrint high-risk patients
had a 10-year DMFS of 87 % (95 %CI 81.9–92.1) with a
HR of 3.62 (95 %CI 1.38–9.50) (p = 0.005). In detail, 38 %
of MammaPrint low-risk patients received adjuvant CT and
91 % received ET. Furthermore, 72 % of MammaPrint
high-risk patients received adjuvant CT and 48 % received
ET. MammaPrint low-risk patients (n = 93) who did not
receive adjuvant CT had a 10-year DMFS of 98 % (95 %CI
94.0–100) and MammaPrint high-risk patients (n = 60) who
did not receive adjuvant CT had a 10-year DMFS of 85 %
(95 %CI 74.8–95.6), data not shown.
Uni-and multivariate analyses were done with the fol-
lowing clinical variables: age, tumor size, grade, ER, and
Her2. Of the clinical variables, grade (3 vs. 1&2) (HR 3.14;
p 0.006), and ER (HR 0.44; p 0.03) reached significance for
10-year DMFS. Age, tumor size, and Her2 were not sig-
nificantly correlated with time to Distant Metastases. Grade
and ER lost their significance in the multivariate analysis,
and only MammaPrint reached near-significance (HR 3.01;
p 0.08) (Table 2).
A sub-analysis of MammaPrint in patients with IHC/
FISH HR-positive and Her2-negative disease also signifi-
cantly predicted 10-year DMFS with a HR of 2.91 (95 %CI
0.97–8.68; p = 0.045). MammaPrint low-risk patients
Fig. 1 Pie charts depicting re-
stratification of patients first
classified according to Clinical
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(n = 142) had a 10-year DMFS of 96 % (95 %CI
92.4–99.4), while MammaPrint high-risk patients (n = 96)
had a 10-year DMFS of 87 % (95 %CI 78.9–95.3)
(Fig. 2b). Moreover, 37 % of these MammaPrint low-risk
patients received adjuvant CT; 92 % received ET; and
53 % of MammaPrint high-risk patients received adjuvant
CT, while 79 % received ET.
Molecular versus clinical subtype 10-year DMFS
There is a significant difference in 10-year DMFS among
different molecular subtypes (p\ 0.001) (Fig. 3a). Lumi-
nal A-type has a 10-year DMFS of 96 % (95 %CI
92.8–99.4) compared to 91 % (95 %CI 84.0–98.2) in
luminal B-type patients; 75 % (95 %CI 60.5–89.1) in
HER2-type patients, and 88 % (95 %CI 79.5–95.5) in
basal-type patients. A sub-analysis of luminal A-type
patients who did not receive adjuvant CT (n = 92) shows a
10-year DMFS of 97 % (95 %CI 93.9–100) (two events at
65 months), while luminal B-type patients who did not
receive adjuvant CT (n = 44) had a 10-year DMFS of
88 % (95 %CI 75.9–99.1). Thirty-eight percent of luminal
A patients received adjuvant CT. We had the opportunity
to evaluate the prognostic value of HER-2 molecular sub-
type in relation to trastuzumab adjuvant treatment.
Approximately, 11 % of HER2-type patients received
adjuvant trastuzumab and they had a 10-year DMFS of
100 %. On the contrary, HER2-type patients who did not
receive adjuvant trastuzumab (n = 33) had a 10-year
DMFS of 72 % (95 %CI 56.5–87.5), data not shown.
Figure 3b shows the analysis of the same patients now
stratified according to surrogate pathology-based clinical
subtyping. The KM-curve shows no significant difference
between the IHC/FISH subgroups. Patients with HR-posi-
tive (‘‘surrogate luminal’’) BC had a 10-year DMFS of
93 % (95 %CI 88.9–96.3) compared to 86 % (95 %CI
76.8–95.2) in patients with Her2-positive breast cancer,
and 90 % (95 %CI 82.8–97.0) in patients with triple-neg-
ative (‘‘surrogate basal’’) breast cancer. Again, 18 % of
Her2-positive patients received adjuvant trastuzumab.
Her2-positive patients who received adjuvant trastuzumab
(n = 11) had a 10-year DMFS of 100 %, while Her2-
positive patients who did not receive adjuvant trastuzumab
(n = 51) had a 10-year DMFS of 83 % (95 %CI
72.6–93.8), data not shown.
Fig. 2 a MammaPrint 10-year DMFS all patients. b MammaPrint
10-year DMFS IHC/FISH HR? HER2- patients
Table 2 Univariate and multivariate analysis of risk of 10-year DMFS
Variable p value Univariate HR Univariate 95 % CI p value Multivariate HR Multivariate 95 % CI
MammaPrint, (High vs. low risk) 0.009 3.623 1.382–9.499 0.080 3.011 0.877–10.333
Age, continuous 0.954 1.001 0.974–1.028 0.440 1.011 0.984–1.039
Tumor size 0.828 0.994 0.944–1.047 0.780 0.991 0.932–1.054
Grade (3 vs. 1&2) 0.006 3.139 1.388–7.097 0.411 1.553 0.544–4.439
ER (pos vs. neg) 0.030 0.440 0.210–0.923 0.559 0.773 0.326–1.834
HER2 (pos vs. neg) 0.087 2.036 0.901–4.597 0.412 1.428 0.609–3.347
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Central re-assessment of discordant BluePrint
and clinical (IHC/FISH) subtypes
Sixty-three out of 373 (17 %) tumors had a discordant
molecular subtype compared to the surrogate pathology-
based IHC/FISH subtype. Fifty-three out of 63 re-classified
tumors were available for central re-assessment of ER, PR,
and HER2 by IHC/SISH. The results are shown in Table 3.
There were 15 tumors locally classified as HR?/HER2-
(‘‘surrogate luminal’’) and not luminal-type by BluePrint.
Central re-assessment confirmed the local result for eight
cases and the BluePrint result for seven cases. There were
27 tumors locally classified as Her2? and not HER2-type
by BluePrint. Central re-assessment confirmed the local
result for seven cases and the BluePrint result for 15 cases.
There were 11 tumors locally classified as triple-negative
(‘‘surrogate basal’’) and not basal-type by BluePrint. Cen-
tral re-assessment confirmed the local result for four cases
and the BluePrint result for six cases. Of all centrally
assessed Her2-positive tumors (n = 10), six were re-clas-
sified as luminal-type by BluePrint molecular classifica-
tion. These six tumors were strongly ER-positive (C80 %),
data not shown.
Discussion
This retrospective study demonstrated that MammaPrint is
able to accurately differentiate between patients at a low
and a high risk of distant metastases up to 10 years after
diagnosis. Patients with a MammaPrint low-risk result have
an excellent 10-year DMFS survival. Remarkably, the
results were consistent among both group of patients, the
cohort that did not receive adjuvant treatment and the one
for which treatment was administered suggesting prog-
nostic and predictive value in the studied population. These
results provide additional confirmation of the clinical
utility for the MammaPrint test as a means of correctly
identifying those patients who may not benefit from the
treatment with adjuvant chemotherapy. The use of genetic
signatures such as MammaPrint for determining which
patients can forego adjuvant chemotherapy treatment has
been accepted by most early-stage BC treatment guidelines
[1, 7]. However, the most optimal diagnostic technique for
stratification of patients for determining endocrine, HER2-
targeted treatment, and correct treatment allocation for
‘‘basal-type’’ patients is openly being questioned in such
guidelines.
The current study on comparison of surrogate versus
gene-expression-based molecular subtype classification of
tumors with 10-year outcome has been performed to aid in
the quest for identifying optimal molecular stratification
assays. The study shows that molecular subtyping with
BluePrint and MammaPrint based on a gene expression
assay leads to a more accurate classification of tumors
with clinically significant prognostic stratification com-
pared to surrogate pathology-based clinical subtypes.
Luminal A patients have an excellent 10 years DMFS of
96 % DMFS, and Luminal B patients have a 10-year
DMFS of 91 % and include also patients who would
otherwise be treated as Her2 or triple-negative patients. In
total, 63 out of 373 (17 %) patients had a different
molecular subtype compared to the surrogate-based
pathologically determined subtype. This percentage of
discordance is in line with percentages seen in other
studies [4, 8]. The discrepancy between molecular- and
Fig. 3 a 10-year DMFS MammaPrint/BluePrint molecular sub-
groups. b 10-year DMFS IHC/FISH subgroups
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surrogate pathology-based clinical subtyping is reasonable
because the two methods are based on different genotypic
features of the tumor; where hormone receptors and HER-
2 are measured individually, BluePrint is designed
according to a rational-based method such that it captures
the functional underlying biologic pathway regulated by
ER, PR, and HER-2 [3].
Six percent of patients with surrogate pathology-based
‘‘luminal’’ (HR?/Her2-) disease were classified as basal-
type BluePrint. This percentage is slightly higher than the
2 % reported earlier in the MINDACT study, in which
tumors were centrally assessed for the pathology-based
subtypes and compared to expression-based BluePrint
subtypes. The higher percentage in the current study may
be explained by the higher threshold for ER-positivity used
prior to 2002 in one of the 2 institutions.
The occurrence of IHC ER? patients classified as basal-
type by BluePrint was previously explained by a relatively
high expression of the dominant-negative ERa-splice
variant ERD7 in ER-positive/basal-type tumors as com-
pared to ER-positive/luminal-type tumors (p\ 0.0001) [9].
Expression of the dominant-negative ERa variant ERD7
provides a rationale as to why tumors are identified as
BluePrint basal-type, while staining ER-positive by IHC;
the BluePrint test appears to measure ER activity inde-
pendent of the ERa mRNA expression level itself. These
tumors may lack a functional response to estrogen and
consequently may not respond to endocrine manipulation
with profound implications for management of these
patients. Similarly, Iwamoto et al. found that most of the
1–9 % IHC ER-positive tumors show molecular features
similar to ER-negative basal-like tumors [10], who suggest
to treat with the safest clinical approach using both adju-
vant endocrine therapy and chemotherapy in this rare
subset of patients. Another study also found that low-ER-
staining tumors were clinic-pathologically more similar to
ER-negative than to ER-positive tumors; 88 % of low-
staining tumors were basal-like or HER2 enriched. Only
those tumors expressing 10 % ER-positive cells were
classified as luminal A subtype [11].
Another group of patients with discordant disease
between surrogate pathology-based and molecular-based
subtyping is the so-called triple-positive disease patient
group: hormonal-positive and Her2? disease. BluePrint
molecular subtyping re-classifies around 50 % of these
patients as luminal-type, with improved prognostic utility:
these patients have an outcome in line with the expected
outcome of Luminal patients. The BluePrint HER2-type
patients, however, have worse outcome compared to clin-
ical Her2-positive patients, and this result was particularly
striking in patients who did not receive trastuzumab. These
data can therefore be regarded as a validation of BluePrint
molecular subtyping as a means of identifying specific
patient groups for treatment allocation. The negative
results for the identification of patients who would have no
benefit from trastuzumab by PAM50-based molecular
subgroups in the NSABP B31 trial presented at SABCS
may have closed the door for molecular subtyping [12].
The development of the two molecular subtyping profiles is
inherently different, where PAM50 was based on unsu-
pervised clustering versus BluePrint which was developed
on a rational-based method, leading to a functional sub-
typing profile [3]. PAM50 classifies approximately 10 % of
clinical luminal/Her2-negative patients as HER2 enriched,
and 17 % of triple-negative patients as Her2 enriched,
potentially diluting the sensitivity of identifying anti-Her2
treatment sensitivity. BluePrint molecular subtyping clas-
sifies less than 1 % of clinical luminal/HER2-negative as
HER2-type and 1 % of triple-negative patients, allowing
the predictive sensitivity for anti Her2 treatment to be
significant between molecularly versus clinically identified
subgroups [8]. In a direct comparative study where patients
are classified according to BluePrint as well as PAM50, the
concordance was only 59 %, indicating that these assays
assign tumors differently [13].
In conclusion, this retrospective non-randomized study
provides valuable insight into the prognostic and predictive
value of molecular testing in patients with early breast
cancer. The unique aspect of the current study is the
combination of both molecular tests allowing to explore the
Table 3 Central re-assessment
of discordant BluePrint and
clinical (IHC/FISH) subtype
cases
Local pathology (IHC/FISH) BluePrint Central pathology (IHC/FISH)
HR?/Her2- Her2? TN Total
HR?/Her2- HER2-type 1 1 0 2
HR?/Her2- Basal-type 7 0 6 13
Her2? Luminal-type 12* 6 1 19
Her2? Basal-type 4 1 3 8
TN Luminal-type 4 0 2 6
TN HER2-type 1 2* 2 5
* Diagnosed between 1996 and 2009 (11 out of 14 diagnosed before 2003)
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potential clinical applications. The increasing availability
of targeted therapies for patients with both luminal and
HER2 subtypes, and the increased use of prolonged adju-
vant endocrine therapy require a more rational approach to
patients’ selection in order to maximize benefits, improve
quality of life, and reduce costs.
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